Engineered donor cells take aim at Hard-to-Treat blood cancers
NCT ID NCT05377827
First seen May 08, 2026 · Last updated May 18, 2026 · Updated 1 time
Summary
This early-phase study tests a new type of CAR T-cell therapy made from donor cells (WU-CART-007) for people with CD7-positive blood cancers, including acute myeloid leukemia and T-cell lymphoma that have not responded to standard treatments. The therapy is designed to target and kill cancer cells while avoiding attacking itself or causing graft-versus-host disease. The main goals are to find a safe dose and check for early signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.